Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms
Neuroendocrinology · 20.05.2026 · 1-15
DOI: 10.1159/000552650 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuroendocrinology, online erschienen am 20.05.2026. Verfasst von Maryam Barsch und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectiology, Medical Center - University of Freiburg, Faculty of Medicine…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Introduction
Neuroendocrine neoplasms (NENs) are rare and biologically heterogeneous tumors with limited evidence-based systemic treatment options, particularly in advanced disease stages. Molecular Tumor Boards (MTBs) offer an interdisciplinary framework for interpreting genomic alterations and identifying personalized treatment strategies.
Methods
We conducted a retrospective two-center analysis of patients with NENs discussed at the MTBs of the University Medical Center Freiburg and the Technical University of Munich between 2019 and 2024. Clinical characteristics, molecular profiling results, MTB-based therapy recommendations, treatment implementation, and outcomes were evaluated. Overall survival (OS) was analyzed using a predefined 6-month landmark approach to account for immortal time bias. Treatment efficacy was further assessed using progression-free survival (PFS) and PFS2/PFS1 ratio.
Results
A total of 87 patients were discussed at both MTBs, 74 of whom underwent molecular profiling. Actionable therapy recommendations were issued for 58 patients, and 20 patients ultimately received MTB-guided therapy. Molecular alterations frequently involved DNA damage repair pathways, immune-related biomarkers, and signaling cascades relevant to targeted therapy. 6-month landmark OS analysis demonstrated significantly improved OS for patients receiving MTB-guided therapy. At the individual level, 8 of 20 treated patients achieved a PFS2/PFS1 ratio >1.3.
Conclusion
Molecular-guided precision oncology can provide clinically meaningful benefit for selected patients with NENs, despite limited overall implementation rates. Earlier integration of molecular profiling may increase the feasibility and impact of personalized treatment approaches in these rare tumor entities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, maryam.barsch@uniklinik-f…
- Clinic for Internal Medicine I, Department of Hematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg im Breisgau, Germany.
- Clinic for Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany.
- Comprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Clinical Department of Internal Medicine II, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany.
Zitieren
APA
Barsch, M., Gräßel, L., Metzger, P., von Werder, A., Ganz, J., Klaas, L., Schulz, L., Decker, A., Dammer, A., Wenzel, P., Friedrich, M., Falkenstein, J., Bertemes, H., Kuehn, J., Miething, C., Lörsch, A. M., Jung, J., Illert, A. L., Kasajima, A., …, & Lange, S. (2026). Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms. Neuroendocrinology, 1-15. https://doi.org/10.1159/000552650
Vancouver
Barsch M, Gräßel L, Metzger P, von Werder A, Ganz J, Klaas L, et al. Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms. Neuroendocrinology. 2026:1-15. doi:10.1159/000552650
BibTeX
@article{Barsch2026,
author = {Barsch, Maryam and Gräßel, Linda and Metzger, Patrick and von Werder, Alexander and Ganz, Johanna and Klaas, Lioba and Schulz, Lisanne and Decker, Annegrit and Dammer, Anna and Wenzel, Patrick and Friedrich, Mathias and Falkenstein, Julia and Bertemes, Henriette and Kuehn, Julia and Miething, Cornelius and Lörsch, Alisa Martina and Jung, Johannes and Illert, Anna Lena and Kasajima, Atsuko and Dorusch, Yasmin and Dopfer, Elaine-Pashupati and Schultheis, Anne Maria and Lassmann, Silke and Pavel, Marianne and Werner, Martin and Boerries, Melanie and Duyster, Justus and Schmid, Roland M and Mogler, Carolin and Pfarr, Nicole and Becker, Heiko and Thimme, Robert and Quante, Michael and Lange, Sebastian},
title = {Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms},
journal = {Neuroendocrinology},
year = {2026},
pages = {1--15},
doi = {10.1159/000552650}
}
EUVIMED